A5111493243- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- Glycosylation and Glycoproteins Research
- CAR-T cell therapy research
- Synthesis and bioactivity of alkaloids
- Liver Diseases and Immunity
- Platelet Disorders and Treatments
- Liver Disease and Transplantation
- Geological Studies and Exploration
- Peripheral Neuropathies and Disorders
- Fibroblast Growth Factor Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Complement system in diseases
- Arctic and Russian Policy Studies
- Environmental Justice and Health Disparities
- Extraction and Separation Processes
- Cancer Genomics and Diagnostics
- Hematopoietic Stem Cell Transplantation
- Monoclonal and Polyclonal Antibodies Research
- Transboundary Water Resource Management
- Fungal Plant Pathogen Control
Universidad Andrés Bello
2024
Centre For Sustainable Urban Development
2024
Pontificia Universidad Católica de Chile
2024
Hospital Clínic de Barcelona
2012-2023
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2014-2023
Universitat de Barcelona
2011-2023
University of California, San Diego
2021
Instituto de Investigación Biomédica de Salamanca
2021
Institut d'Investigacions Biomèdiques de Barcelona
2020
Parkside Hospital
2011
Multiple myeloma (MM) remains incurable despite the number of novel therapies that have become available in recent years. Occasionally, a patient with MM will develop an amyloid light-chain (AL) amyloidosis organ dysfunction. Chimeric antigen receptor T-cell (CART) therapy has promising approach treating hematological malignancies. Our institution developed second-generation B-cell maturation (BCMA)–CART which is currently being tested clinical trial for relapsed/refractory MM. We present...
The calibration and validation of a hydrodynamic model for water level prediction over the Gulf Nicoya estuary using Delft3D-FM simulation environment developed by Deltares is shown. For environment, an irregular grid in three dimensions was used gulf region that contemplates shallow waters (less than 80 m). Calibration performed dry rainy seasons considering different variations input conditions consider river discharges, wind variation number layers vertical. Subsequently, stages involving...
Summary. In a uniform series of 170 untreated myeloma patients (MM) we investigated the distribution T cell subsets in peripheral blood (PB) and their relationship with most relevant disease characteristics, including survival. CD4 cells were significantly decreased both percentage absolute numbers ( P < 0.0001). On other hand, CD8 only showed slight increase relative numbers. Upon correlating abnormalities clinical biological characteristics remarkable correlation was A low number (<...
Summary Carfilzomib has been associated with the development of thrombotic microangiopathy (TMA) in relapsed/refractory multiple myeloma patients, a severe disease no currently available aetiological treatment. We evaluated potential role terminal complement pathway four patients carfilzomib‐induced TMA. Membrane attack complex (C5b‐9) deposition on endothelial cells culture exposed to plasma from during acute phase suggests overactivation as mechanism damage three out patients. If confirmed...
Multiple myeloma (MM) is considered an incurable hematological neoplasm. For transplant-eligible patients, initial treatment includes induction phase followed by autologous stem cell transplantation (ASCT). Despite the introduction of several drugs in past years, relapses still occur. Nevertheless, some patients achieve sustained responses after successful and ASCT.We retrospectively evaluated all diagnosed with MM our institution who underwent ASCT between 1990 2015. The subset achieved a...